Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
PPHvsETF 2ETF Comparison
Choose a second ETF to run a side-by-side ETF comparison with PPH, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
PPH performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | PPH ETF 2 | -3.86%– | +6.18%– | +2.84%– | +16.88%– | +52.87%– | +69.42%– |
| Flows | PPH ETF 2 | +$109M– | +$36M– | -$22M– | +$492M– | +$676M– | +$859M– |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | PPH ETF 2 | +15.81%– | +19.48%– | +14.76%– | +14.72%– |
| Max drawdown | PPH ETF 2 | -5.13%– | -13.53%– | -17.98%– | -20.19%– |
| Max drawdown duration | PPH ETF 2 | 10d– | 196d– | 434d– | 484d– |
PPH | ETF 2 | |
Last sale 3/12/2026 at 1:30 PM | $104.72 | – |
| Previous close 03/11/2026 | $106.04 | – |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
PPH | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
PPH | ETF 2 | |
|---|---|---|
| Last price | $104.72 | – |
| 1D performance | -1.24% | – |
| AuM | $1.29 B | – |
| E/R | 0.36% | – |
PPH | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | VanEck | – |
| Benchmark | MVIS US Listed Pharmaceutical 25 Index | – |
| N° of holdings | 18 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 20, 2011 | – |
| ESG | No | – |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Top 15 holdings
Healthcare Stocks Rebound
Investing in the Aging Population: A Look at Bonds and Pharma ETFs
Trending sub-sectors in 2022
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
